Fragment-based Drug Discovery research
Fragment-based Drug Discovery research

Fragment-based Drug Discovery Comprehensive Study by Type (Fragment Screening, Fragment Optimization), End-users (Academic and Research Institutions, Biopharmaceutical Companies, Contract Research Organizations), Technology (NMR Spectroscopy, Differential Scanning Fluorimetry (DSF) Assay, Fluorescence Polarization, Isothermal Titration Calorimetry, X-Ray Crystallography, Surface Plasmon Resonance (SPR), Others) Players and Region - Global Market Outlook to 2027

Fragment-based Drug Discovery Market Segmented into XX Submarkets. | Forecast Years: 2022- 2027  

Apr 2022 Edition 233 Pages 215 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Fragment-based Drug Discovery?
Fragment-based drug discovery (FBDD) additionally acknowledged as fragment-based lead discovery (FBLD) is a technique used for discovering lead compounds as section of the drug discovery process. Fragments are small natural molecules which are small in dimension and low in molecular weight. It is based totally on figuring out small chemical fragments, which may also bind solely weakly to the organic target, and then developing them or combining them to produce a lead with a greater affinity. Fragment-based drug discovery (FBDD) is a effective approach to enhance powerful small-molecule compounds beginning from fragments binding weakly to targets. As FBDD famous a number of blessings over high-throughput screening campaigns, it will become an appealing method in target-based drug discovery.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledAstex Pharmaceuticals (United Kingdom), Alveus Pharmaceuticals (India), Beactica (Sweden), Charles River Laboratories (United States), Crown Bioscience (United States), Emerald BioStructures (United States), Evotec (Germany), Kinetic Discovery (United Kingdom), Proteros Fragments (Germany) and Structure Based Design (United States)
CAGR%


The market study is broken down by Type (Fragment Screening and Fragment Optimization) and major geographies with country level break-up.

The market is seeing moderate market players, by seeing huge growth in this market the key leading vendors are highly focusing towards the production technologies, efficiency enhancement and product life. There is various growth opportunity in this market which is captured by leading players via tracking the ongoing process enhancement and huge invest in market growth strategies. Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global Fragment-based Drug Discovery market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Astex Pharmaceuticals (United Kingdom), Alveus Pharmaceuticals (India), Beactica (Sweden), Charles River Laboratories (United States), Crown Bioscience (United States), Emerald BioStructures (United States), Evotec (Germany), Kinetic Discovery (United Kingdom), Proteros Fragments (Germany) and Structure Based Design (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Sygnature Discovery (United Kingdom) and Sprint Bioscience (Sweden).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Fragment-based Drug Discovery market by Type, Application and Region.

On the basis of geography, the market of Fragment-based Drug Discovery has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End-users, the sub-segment i.e. Academic and Research Institutions will boost the Fragment-based Drug Discovery market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Technology, the sub-segment i.e. NMR Spectroscopy will boost the Fragment-based Drug Discovery market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

In 2021, Astex Pharmaceuticals, Inc., a utterly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., primarily based in Tokyo, Japan, introduced up to date medical data, which includes median normal survival (mOS), from the ASCERTAIN section three trial of INQOVI®, the company’s orally administered fixed-dose aggregate of decitabine and cedazuridine (ASTX727 or DEC-C) in adults with intermediate and high-risk myelodysplastic syndromes (MDS) together with continual myelomonocytic leukemia (CMML).


Market Trend
  • High-Tech Will Fuel Advancement in R&D
  • Data Analytics Will Accelerate Biotechnology Innovation
  • Emerging Markets Will Drive Innovation
  • Increased Conflict between Affordability and Access

Market Drivers
  • Increasingly used in the Pharmaceutical Industry, For Reducing Attrition and Providing Leads for Previously Intractable Biological Targets
  • Availability of Wide Range of Assay Options for High Hit Rates of Fragment-Based Screens


Restraints
  • It is a complex Method
  • Expensive Method

Challenges
  • Reduced Demand for Prescription Medicine
  • Growing Competition from Generic Pharmaceuticals
  • Pharmaceutical Fraud
  • Rising Consumer Expectations and Difficulties Managing Brand Health
  • Data Breaches and Other Cybersecurity Threats
  • Supply Chain Disruptions


Key Target Audience
Fragmented-based Drug Discovery Manufacturers, Raw Materials Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Frequently Asked Questions (FAQ):

1. What all players are profiled in the study?
The standard version of the report profiles players such as Astex Pharmaceuticals (United Kingdom), Alveus Pharmaceuticals (India), Beactica (Sweden), Charles River Laboratories (United States), Crown Bioscience (United States), Emerald BioStructures (United States), Evotec (Germany), Kinetic Discovery (United Kingdom), Proteros Fragments (Germany) and Structure Based Design (United States) etc.

2. Can we have customized study for Fragment-based Drug Discovery Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

3. What would be the Market Size of Fragment-based Drug Discovery Market by 2027?
Analysts at AMA estimates Fragment-based Drug Discovery Market to reach USD Million by 2027.
Report Objectives / Segmentation Covered
By Type
  • Fragment Screening
  • Fragment Optimization
By End-users
  • Academic and Research Institutions
  • Biopharmaceutical Companies
  • Contract Research Organizations

By Technology
  • NMR Spectroscopy
  • Differential Scanning Fluorimetry (DSF) Assay
  • Fluorescence Polarization
  • Isothermal Titration Calorimetry
  • X-Ray Crystallography
  • Surface Plasmon Resonance (SPR)
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasingly used in the Pharmaceutical Industry, For Reducing Attrition and Providing Leads for Previously Intractable Biological Targets
      • 3.2.2. Availability of Wide Range of Assay Options for High Hit Rates of Fragment-Based Screens
    • 3.3. Market Challenges
      • 3.3.1. Reduced Demand for Prescription Medicine
      • 3.3.2. Growing Competition from Generic Pharmaceuticals
      • 3.3.3. Pharmaceutical Fraud
      • 3.3.4. Rising Consumer Expectations and Difficulties Managing Brand Health
      • 3.3.5. Data Breaches and Other Cybersecurity Threats
      • 3.3.6. Supply Chain Disruptions
    • 3.4. Market Trends
      • 3.4.1. High-Tech Will Fuel Advancement in R&D
      • 3.4.2. Data Analytics Will Accelerate Biotechnology Innovation
      • 3.4.3. Emerging Markets Will Drive Innovation
      • 3.4.4. Increased Conflict between Affordability and Access
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Fragment-based Drug Discovery, by Type, End-users, Technology and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Fragment-based Drug Discovery (Value)
      • 5.2.1. Global Fragment-based Drug Discovery by: Type (Value)
        • 5.2.1.1. Fragment Screening
        • 5.2.1.2. Fragment Optimization
      • 5.2.2. Global Fragment-based Drug Discovery by: End-users (Value)
        • 5.2.2.1. Academic and Research Institutions
        • 5.2.2.2. Biopharmaceutical Companies
        • 5.2.2.3. Contract Research Organizations
      • 5.2.3. Global Fragment-based Drug Discovery by: Technology (Value)
        • 5.2.3.1. NMR Spectroscopy
        • 5.2.3.2. Differential Scanning Fluorimetry (DSF) Assay
        • 5.2.3.3. Fluorescence Polarization
        • 5.2.3.4. Isothermal Titration Calorimetry
        • 5.2.3.5. X-Ray Crystallography
        • 5.2.3.6. Surface Plasmon Resonance (SPR)
        • 5.2.3.7. Others
      • 5.2.4. Global Fragment-based Drug Discovery Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Fragment-based Drug Discovery: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Astex Pharmaceuticals (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Alveus Pharmaceuticals (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Beactica (Sweden)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Charles River Laboratories (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Crown Bioscience (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Emerald BioStructures (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Evotec (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Kinetic Discovery (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Proteros Fragments (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Structure Based Design (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Fragment-based Drug Discovery Sale, by Type, End-users, Technology and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Fragment-based Drug Discovery (Value)
      • 7.2.1. Global Fragment-based Drug Discovery by: Type (Value)
        • 7.2.1.1. Fragment Screening
        • 7.2.1.2. Fragment Optimization
      • 7.2.2. Global Fragment-based Drug Discovery by: End-users (Value)
        • 7.2.2.1. Academic and Research Institutions
        • 7.2.2.2. Biopharmaceutical Companies
        • 7.2.2.3. Contract Research Organizations
      • 7.2.3. Global Fragment-based Drug Discovery by: Technology (Value)
        • 7.2.3.1. NMR Spectroscopy
        • 7.2.3.2. Differential Scanning Fluorimetry (DSF) Assay
        • 7.2.3.3. Fluorescence Polarization
        • 7.2.3.4. Isothermal Titration Calorimetry
        • 7.2.3.5. X-Ray Crystallography
        • 7.2.3.6. Surface Plasmon Resonance (SPR)
        • 7.2.3.7. Others
      • 7.2.4. Global Fragment-based Drug Discovery Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Fragment-based Drug Discovery: by Type(USD Million)
  • Table 2. Fragment-based Drug Discovery Fragment Screening , by Region USD Million (2016-2021)
  • Table 3. Fragment-based Drug Discovery Fragment Optimization , by Region USD Million (2016-2021)
  • Table 4. Fragment-based Drug Discovery: by End-users(USD Million)
  • Table 5. Fragment-based Drug Discovery Academic and Research Institutions , by Region USD Million (2016-2021)
  • Table 6. Fragment-based Drug Discovery Biopharmaceutical Companies , by Region USD Million (2016-2021)
  • Table 7. Fragment-based Drug Discovery Contract Research Organizations , by Region USD Million (2016-2021)
  • Table 8. Fragment-based Drug Discovery: by Technology(USD Million)
  • Table 9. Fragment-based Drug Discovery NMR Spectroscopy , by Region USD Million (2016-2021)
  • Table 10. Fragment-based Drug Discovery Differential Scanning Fluorimetry (DSF) Assay , by Region USD Million (2016-2021)
  • Table 11. Fragment-based Drug Discovery Fluorescence Polarization , by Region USD Million (2016-2021)
  • Table 12. Fragment-based Drug Discovery Isothermal Titration Calorimetry , by Region USD Million (2016-2021)
  • Table 13. Fragment-based Drug Discovery X-Ray Crystallography , by Region USD Million (2016-2021)
  • Table 14. Fragment-based Drug Discovery Surface Plasmon Resonance (SPR) , by Region USD Million (2016-2021)
  • Table 15. Fragment-based Drug Discovery Others , by Region USD Million (2016-2021)
  • Table 16. South America Fragment-based Drug Discovery, by Country USD Million (2016-2021)
  • Table 17. South America Fragment-based Drug Discovery, by Type USD Million (2016-2021)
  • Table 18. South America Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
  • Table 19. South America Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
  • Table 20. Brazil Fragment-based Drug Discovery, by Type USD Million (2016-2021)
  • Table 21. Brazil Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
  • Table 22. Brazil Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
  • Table 23. Argentina Fragment-based Drug Discovery, by Type USD Million (2016-2021)
  • Table 24. Argentina Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
  • Table 25. Argentina Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
  • Table 26. Rest of South America Fragment-based Drug Discovery, by Type USD Million (2016-2021)
  • Table 27. Rest of South America Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
  • Table 28. Rest of South America Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
  • Table 29. Asia Pacific Fragment-based Drug Discovery, by Country USD Million (2016-2021)
  • Table 30. Asia Pacific Fragment-based Drug Discovery, by Type USD Million (2016-2021)
  • Table 31. Asia Pacific Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
  • Table 32. Asia Pacific Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
  • Table 33. China Fragment-based Drug Discovery, by Type USD Million (2016-2021)
  • Table 34. China Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
  • Table 35. China Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
  • Table 36. Japan Fragment-based Drug Discovery, by Type USD Million (2016-2021)
  • Table 37. Japan Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
  • Table 38. Japan Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
  • Table 39. India Fragment-based Drug Discovery, by Type USD Million (2016-2021)
  • Table 40. India Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
  • Table 41. India Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
  • Table 42. South Korea Fragment-based Drug Discovery, by Type USD Million (2016-2021)
  • Table 43. South Korea Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
  • Table 44. South Korea Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
  • Table 45. Taiwan Fragment-based Drug Discovery, by Type USD Million (2016-2021)
  • Table 46. Taiwan Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
  • Table 47. Taiwan Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
  • Table 48. Australia Fragment-based Drug Discovery, by Type USD Million (2016-2021)
  • Table 49. Australia Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
  • Table 50. Australia Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
  • Table 51. Rest of Asia-Pacific Fragment-based Drug Discovery, by Type USD Million (2016-2021)
  • Table 52. Rest of Asia-Pacific Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
  • Table 53. Rest of Asia-Pacific Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
  • Table 54. Europe Fragment-based Drug Discovery, by Country USD Million (2016-2021)
  • Table 55. Europe Fragment-based Drug Discovery, by Type USD Million (2016-2021)
  • Table 56. Europe Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
  • Table 57. Europe Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
  • Table 58. Germany Fragment-based Drug Discovery, by Type USD Million (2016-2021)
  • Table 59. Germany Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
  • Table 60. Germany Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
  • Table 61. France Fragment-based Drug Discovery, by Type USD Million (2016-2021)
  • Table 62. France Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
  • Table 63. France Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
  • Table 64. Italy Fragment-based Drug Discovery, by Type USD Million (2016-2021)
  • Table 65. Italy Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
  • Table 66. Italy Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
  • Table 67. United Kingdom Fragment-based Drug Discovery, by Type USD Million (2016-2021)
  • Table 68. United Kingdom Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
  • Table 69. United Kingdom Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
  • Table 70. Netherlands Fragment-based Drug Discovery, by Type USD Million (2016-2021)
  • Table 71. Netherlands Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
  • Table 72. Netherlands Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
  • Table 73. Rest of Europe Fragment-based Drug Discovery, by Type USD Million (2016-2021)
  • Table 74. Rest of Europe Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
  • Table 75. Rest of Europe Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
  • Table 76. MEA Fragment-based Drug Discovery, by Country USD Million (2016-2021)
  • Table 77. MEA Fragment-based Drug Discovery, by Type USD Million (2016-2021)
  • Table 78. MEA Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
  • Table 79. MEA Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
  • Table 80. Middle East Fragment-based Drug Discovery, by Type USD Million (2016-2021)
  • Table 81. Middle East Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
  • Table 82. Middle East Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
  • Table 83. Africa Fragment-based Drug Discovery, by Type USD Million (2016-2021)
  • Table 84. Africa Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
  • Table 85. Africa Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
  • Table 86. North America Fragment-based Drug Discovery, by Country USD Million (2016-2021)
  • Table 87. North America Fragment-based Drug Discovery, by Type USD Million (2016-2021)
  • Table 88. North America Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
  • Table 89. North America Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
  • Table 90. United States Fragment-based Drug Discovery, by Type USD Million (2016-2021)
  • Table 91. United States Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
  • Table 92. United States Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
  • Table 93. Canada Fragment-based Drug Discovery, by Type USD Million (2016-2021)
  • Table 94. Canada Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
  • Table 95. Canada Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
  • Table 96. Mexico Fragment-based Drug Discovery, by Type USD Million (2016-2021)
  • Table 97. Mexico Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
  • Table 98. Mexico Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Fragment-based Drug Discovery: by Type(USD Million)
  • Table 110. Fragment-based Drug Discovery Fragment Screening , by Region USD Million (2022-2027)
  • Table 111. Fragment-based Drug Discovery Fragment Optimization , by Region USD Million (2022-2027)
  • Table 112. Fragment-based Drug Discovery: by End-users(USD Million)
  • Table 113. Fragment-based Drug Discovery Academic and Research Institutions , by Region USD Million (2022-2027)
  • Table 114. Fragment-based Drug Discovery Biopharmaceutical Companies , by Region USD Million (2022-2027)
  • Table 115. Fragment-based Drug Discovery Contract Research Organizations , by Region USD Million (2022-2027)
  • Table 116. Fragment-based Drug Discovery: by Technology(USD Million)
  • Table 117. Fragment-based Drug Discovery NMR Spectroscopy , by Region USD Million (2022-2027)
  • Table 118. Fragment-based Drug Discovery Differential Scanning Fluorimetry (DSF) Assay , by Region USD Million (2022-2027)
  • Table 119. Fragment-based Drug Discovery Fluorescence Polarization , by Region USD Million (2022-2027)
  • Table 120. Fragment-based Drug Discovery Isothermal Titration Calorimetry , by Region USD Million (2022-2027)
  • Table 121. Fragment-based Drug Discovery X-Ray Crystallography , by Region USD Million (2022-2027)
  • Table 122. Fragment-based Drug Discovery Surface Plasmon Resonance (SPR) , by Region USD Million (2022-2027)
  • Table 123. Fragment-based Drug Discovery Others , by Region USD Million (2022-2027)
  • Table 124. South America Fragment-based Drug Discovery, by Country USD Million (2022-2027)
  • Table 125. South America Fragment-based Drug Discovery, by Type USD Million (2022-2027)
  • Table 126. South America Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
  • Table 127. South America Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
  • Table 128. Brazil Fragment-based Drug Discovery, by Type USD Million (2022-2027)
  • Table 129. Brazil Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
  • Table 130. Brazil Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
  • Table 131. Argentina Fragment-based Drug Discovery, by Type USD Million (2022-2027)
  • Table 132. Argentina Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
  • Table 133. Argentina Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
  • Table 134. Rest of South America Fragment-based Drug Discovery, by Type USD Million (2022-2027)
  • Table 135. Rest of South America Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
  • Table 136. Rest of South America Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
  • Table 137. Asia Pacific Fragment-based Drug Discovery, by Country USD Million (2022-2027)
  • Table 138. Asia Pacific Fragment-based Drug Discovery, by Type USD Million (2022-2027)
  • Table 139. Asia Pacific Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
  • Table 140. Asia Pacific Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
  • Table 141. China Fragment-based Drug Discovery, by Type USD Million (2022-2027)
  • Table 142. China Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
  • Table 143. China Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
  • Table 144. Japan Fragment-based Drug Discovery, by Type USD Million (2022-2027)
  • Table 145. Japan Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
  • Table 146. Japan Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
  • Table 147. India Fragment-based Drug Discovery, by Type USD Million (2022-2027)
  • Table 148. India Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
  • Table 149. India Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
  • Table 150. South Korea Fragment-based Drug Discovery, by Type USD Million (2022-2027)
  • Table 151. South Korea Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
  • Table 152. South Korea Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
  • Table 153. Taiwan Fragment-based Drug Discovery, by Type USD Million (2022-2027)
  • Table 154. Taiwan Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
  • Table 155. Taiwan Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
  • Table 156. Australia Fragment-based Drug Discovery, by Type USD Million (2022-2027)
  • Table 157. Australia Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
  • Table 158. Australia Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
  • Table 159. Rest of Asia-Pacific Fragment-based Drug Discovery, by Type USD Million (2022-2027)
  • Table 160. Rest of Asia-Pacific Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
  • Table 161. Rest of Asia-Pacific Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
  • Table 162. Europe Fragment-based Drug Discovery, by Country USD Million (2022-2027)
  • Table 163. Europe Fragment-based Drug Discovery, by Type USD Million (2022-2027)
  • Table 164. Europe Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
  • Table 165. Europe Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
  • Table 166. Germany Fragment-based Drug Discovery, by Type USD Million (2022-2027)
  • Table 167. Germany Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
  • Table 168. Germany Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
  • Table 169. France Fragment-based Drug Discovery, by Type USD Million (2022-2027)
  • Table 170. France Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
  • Table 171. France Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
  • Table 172. Italy Fragment-based Drug Discovery, by Type USD Million (2022-2027)
  • Table 173. Italy Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
  • Table 174. Italy Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
  • Table 175. United Kingdom Fragment-based Drug Discovery, by Type USD Million (2022-2027)
  • Table 176. United Kingdom Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
  • Table 177. United Kingdom Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
  • Table 178. Netherlands Fragment-based Drug Discovery, by Type USD Million (2022-2027)
  • Table 179. Netherlands Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
  • Table 180. Netherlands Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
  • Table 181. Rest of Europe Fragment-based Drug Discovery, by Type USD Million (2022-2027)
  • Table 182. Rest of Europe Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
  • Table 183. Rest of Europe Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
  • Table 184. MEA Fragment-based Drug Discovery, by Country USD Million (2022-2027)
  • Table 185. MEA Fragment-based Drug Discovery, by Type USD Million (2022-2027)
  • Table 186. MEA Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
  • Table 187. MEA Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
  • Table 188. Middle East Fragment-based Drug Discovery, by Type USD Million (2022-2027)
  • Table 189. Middle East Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
  • Table 190. Middle East Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
  • Table 191. Africa Fragment-based Drug Discovery, by Type USD Million (2022-2027)
  • Table 192. Africa Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
  • Table 193. Africa Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
  • Table 194. North America Fragment-based Drug Discovery, by Country USD Million (2022-2027)
  • Table 195. North America Fragment-based Drug Discovery, by Type USD Million (2022-2027)
  • Table 196. North America Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
  • Table 197. North America Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
  • Table 198. United States Fragment-based Drug Discovery, by Type USD Million (2022-2027)
  • Table 199. United States Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
  • Table 200. United States Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
  • Table 201. Canada Fragment-based Drug Discovery, by Type USD Million (2022-2027)
  • Table 202. Canada Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
  • Table 203. Canada Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
  • Table 204. Mexico Fragment-based Drug Discovery, by Type USD Million (2022-2027)
  • Table 205. Mexico Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
  • Table 206. Mexico Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
  • Table 207. Research Programs/Design for This Report
  • Table 208. Key Data Information from Secondary Sources
  • Table 209. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Fragment-based Drug Discovery: by Type USD Million (2016-2021)
  • Figure 5. Global Fragment-based Drug Discovery: by End-users USD Million (2016-2021)
  • Figure 6. Global Fragment-based Drug Discovery: by Technology USD Million (2016-2021)
  • Figure 7. South America Fragment-based Drug Discovery Share (%), by Country
  • Figure 8. Asia Pacific Fragment-based Drug Discovery Share (%), by Country
  • Figure 9. Europe Fragment-based Drug Discovery Share (%), by Country
  • Figure 10. MEA Fragment-based Drug Discovery Share (%), by Country
  • Figure 11. North America Fragment-based Drug Discovery Share (%), by Country
  • Figure 12. Global Fragment-based Drug Discovery share by Players 2021 (%)
  • Figure 13. Global Fragment-based Drug Discovery share by Players (Top 3) 2021(%)
  • Figure 14. Global Fragment-based Drug Discovery share by Players (Top 5) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Astex Pharmaceuticals (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. Astex Pharmaceuticals (United Kingdom) Revenue: by Geography 2021
  • Figure 18. Alveus Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 19. Alveus Pharmaceuticals (India) Revenue: by Geography 2021
  • Figure 20. Beactica (Sweden) Revenue, Net Income and Gross profit
  • Figure 21. Beactica (Sweden) Revenue: by Geography 2021
  • Figure 22. Charles River Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 23. Charles River Laboratories (United States) Revenue: by Geography 2021
  • Figure 24. Crown Bioscience (United States) Revenue, Net Income and Gross profit
  • Figure 25. Crown Bioscience (United States) Revenue: by Geography 2021
  • Figure 26. Emerald BioStructures (United States) Revenue, Net Income and Gross profit
  • Figure 27. Emerald BioStructures (United States) Revenue: by Geography 2021
  • Figure 28. Evotec (Germany) Revenue, Net Income and Gross profit
  • Figure 29. Evotec (Germany) Revenue: by Geography 2021
  • Figure 30. Kinetic Discovery (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. Kinetic Discovery (United Kingdom) Revenue: by Geography 2021
  • Figure 32. Proteros Fragments (Germany) Revenue, Net Income and Gross profit
  • Figure 33. Proteros Fragments (Germany) Revenue: by Geography 2021
  • Figure 34. Structure Based Design (United States) Revenue, Net Income and Gross profit
  • Figure 35. Structure Based Design (United States) Revenue: by Geography 2021
  • Figure 36. Global Fragment-based Drug Discovery: by Type USD Million (2022-2027)
  • Figure 37. Global Fragment-based Drug Discovery: by End-users USD Million (2022-2027)
  • Figure 38. Global Fragment-based Drug Discovery: by Technology USD Million (2022-2027)
  • Figure 39. South America Fragment-based Drug Discovery Share (%), by Country
  • Figure 40. Asia Pacific Fragment-based Drug Discovery Share (%), by Country
  • Figure 41. Europe Fragment-based Drug Discovery Share (%), by Country
  • Figure 42. MEA Fragment-based Drug Discovery Share (%), by Country
  • Figure 43. North America Fragment-based Drug Discovery Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Astex Pharmaceuticals (United Kingdom)
  • Alveus Pharmaceuticals (India)
  • Beactica (Sweden)
  • Charles River Laboratories (United States)
  • Crown Bioscience (United States)
  • Emerald BioStructures (United States)
  • Evotec (Germany)
  • Kinetic Discovery (United Kingdom)
  • Proteros Fragments (Germany)
  • Structure Based Design (United States)
Additional players considered in the study are as follows:
Sygnature Discovery (United Kingdom) , Sprint Bioscience (Sweden)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation